🚀 VC round data is live in beta, check it out!
Lipocine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lipocine and similar public comparables like Intercure, NextCure, Estrella Immunopharma, Prescient Therapeutics and more.
Lipocine Overview
About Lipocine
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP’RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Founded
1997
HQ
Employees
16
Website
Sectors
Financials (LTM)
EV
$30M
Lipocine Financials
Lipocine reported last 12-month revenue of $2M.
In the same LTM period, Lipocine generated had net loss of ($11M).
Revenue (LTM)
Lipocine P&L
In the most recent fiscal year, Lipocine reported revenue of $2M and EBITDA of ($10M).
Lipocine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($7M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (334%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($10M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (522%) | XXX | XXX | XXX |
| EBIT Margin | (674%) | XXX | (525%) | XXX | XXX | XXX |
| Net Profit | ($11M) | XXX | ($10M) | XXX | XXX | XXX |
| Net Margin | (635%) | XXX | (487%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lipocine Stock Performance
Lipocine has current market cap of $45M, and enterprise value of $30M.
Market Cap Evolution
Lipocine's stock price is $8.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30M | $45M | 0.0% | XXX | XXX | XXX | $-1.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLipocine Valuation Multiples
Lipocine trades at 17.9x EV/Revenue multiple, and (2.9x) EV/EBITDA.
EV / Revenue (LTM)
Lipocine Financial Valuation Multiples
As of March 21, 2026, Lipocine has market cap of $45M and EV of $30M.
Equity research analysts estimate Lipocine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lipocine has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV/Revenue | 17.9x | XXX | 15.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.9x) | XXX | XXX | XXX |
| EV/EBIT | (2.7x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (4.6x) | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lipocine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lipocine Margins & Growth Rates
Lipocine's revenue in the last 12 month declined by (56%).
Lipocine's revenue per employee in the last FY averaged $0.1M.
Lipocine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (56%) | XXX | (67%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (522%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 826% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 223% | XXX | 190% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 551% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 190% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lipocine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Intercure | XXX | XXX | XXX | XXX | XXX | XXX |
| NextCure | XXX | XXX | XXX | XXX | XXX | XXX |
| Estrella Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lipocine M&A Activity
Lipocine acquired XXX companies to date.
Last acquisition by Lipocine was on XXXXXXXX, XXXXX. Lipocine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lipocine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLipocine Investment Activity
Lipocine invested in XXX companies to date.
Lipocine made its latest investment on XXXXXXXX, XXXXX. Lipocine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lipocine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lipocine
| When was Lipocine founded? | Lipocine was founded in 1997. |
| Where is Lipocine headquartered? | Lipocine is headquartered in United States. |
| How many employees does Lipocine have? | As of today, Lipocine has over 16 employees. |
| Who is the CEO of Lipocine? | Lipocine's CEO is Mahesh V. Patel. |
| Is Lipocine publicly listed? | Yes, Lipocine is a public company listed on Nasdaq. |
| What is the stock symbol of Lipocine? | Lipocine trades under LPCN ticker. |
| When did Lipocine go public? | Lipocine went public in 2012. |
| Who are competitors of Lipocine? | Lipocine main competitors are Intercure, NextCure, Estrella Immunopharma, Prescient Therapeutics. |
| What is the current market cap of Lipocine? | Lipocine's current market cap is $45M. |
| What is the current revenue of Lipocine? | Lipocine's last 12 months revenue is $2M. |
| What is the current revenue growth of Lipocine? | Lipocine revenue growth (NTM/LTM) is (56%). |
| What is the current EV/Revenue multiple of Lipocine? | Current revenue multiple of Lipocine is 17.9x. |
| Is Lipocine profitable? | No, Lipocine is not profitable. |
| What is the current net income of Lipocine? | Lipocine's last 12 months net income is ($11M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.